Dacomitinib(Vizimpro)

Dacomitinib is a prescription drug targeting the human epidermal growth factor receptor (EGFR) family. It was approved by the U.S. FDA on September 27, 2018, and should be used strictly under medical supervision.

Target of Action

Human epidermal growth factor receptor (EGFR) family

Dosage and Administration

Route and frequency of administration for Dacomitinib: oral, once daily.

Dacomitinib dosage should be adjusted based on the patient's actual condition; specific adjustments require consultation with a physician and adherence to medical advice.

Recommended reading: Dosage and Administration of Dacomitinib

Side Effects

Common side effects: diarrhea, rash, paronychia, etc.

Serious side effects: interstitial lung disease (ILD), severe diarrhea, severe rash, etc.

Reference article: Side Effects of Dacomitinib

Use in Special Populations

Pregnancy: Advise females of reproductive potential to use effective contraception during treatment with Dacomitinib and for at least 17 days after the final dose.

Lactation: Due to the potential for serious adverse reactions in breastfed infants from Dacomitinib, advise women not to breastfeed during treatment with Dacomitinib and for at least 17 days after the final dose.

Daily Precautions

1. Instruct patients to take the medication at approximately the same time each day.

2. If a dose is missed or vomiting occurs after dosing, advise patients to take the next dose at the regularly scheduled time; do not take an extra dose to make up for the missed dose.

3. Instruct patients to use moisturizers at the start of Dacomitinib therapy, and to reduce sun exposure by wearing protective clothing and applying sunscreen.

from FDA，2020.12